Cargando…

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

INTRODUCTION: Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier for the treatment of patients with spinal muscular atrophy (SMA). The JEWELFISH study (NCT03032172) was designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of risdiplam in previ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiriboga, Claudia A., Bruno, Claudio, Duong, Tina, Fischer, Dirk, Mercuri, Eugenio, Kirschner, Janbernd, Kostera-Pruszczyk, Anna, Jaber, Birgit, Gorni, Ksenija, Kletzl, Heidemarie, Carruthers, Imogen, Martin, Carmen, Warren, Francis, Scalco, Renata S., Wagner, Kathryn R., Muntoni, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924181/ https://www.ncbi.nlm.nih.gov/pubmed/36780114 http://dx.doi.org/10.1007/s40120-023-00444-1

Ejemplares similares

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
por: Sergott, Robert C., et al.
Publicado: (2020)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
por: Kwon, Jennifer M., et al.
Publicado: (2022)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
por: MacCannell, Drew, et al.
Publicado: (2022)

Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qiao, Yue, et al.
Publicado: (2023)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
por: Krupa, Dominika, et al.
Publicado: (2023)

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States
por: Darras, Basil T., et al.
Publicado: (2022)

Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
por: Schorling, David C., et al.
Publicado: (2020)

Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
por: Cances, Claude, et al.
Publicado: (2022)

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
por: Kiefer, Petra, et al.
Publicado: (2020)

RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design
por: Finkel, Richard S., et al.
Publicado: (2020)

Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis
por: Rosiak, Grzegorz, et al.
Publicado: (2021)

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
por: Lo, Siu Hing, et al.
Publicado: (2021)

Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience
por: Friese, Johannes, et al.
Publicado: (2021)

Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures
por: Aponte Ribero, Valerie, et al.
Publicado: (2023)

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data
por: Duong, Tina, et al.
Publicado: (2022)

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
por: De Vivo, Darryl C., et al.
Publicado: (2019)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
por: Poirier, Agnès, et al.
Publicado: (2018)

Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
por: Łusakowska, Anna, et al.
Publicado: (2023)

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
por: Pechmann, Astrid, et al.
Publicado: (2019)

Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives
por: DE LOS ANGELES BEYTÍA, MARIA, et al.
Publicado: (2012)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_22n31s8cqcp9pr38sr3tgnhg78